NCT01377298View on ClinicalTrials.gov

Pazopanib in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

PHASE2UnknownINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

May 31, 2013

Study Completion Date

May 31, 2014

Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
DRUG

Pazopanib

200mg/tablet, 800mg/day PO.

Trial Locations (1)

100

RECRUITING

National Taiwan University Hospital, Taipei

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

National Taiwan University Hospital

OTHER

NCT01377298 - Pazopanib in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | Biotech Hunter | Biotech Hunter